Status og perspektiver for behandling af de kroniske myeloproliferative neoplasier

Translated title of the contribution: Status and perspectives on chronic myeloproliferative neoplasm treatment

Lukas Frans Ocias, Morten Orebo Holmström, Caroline Hasselbalch Riley, Christen Lykkegaard Andersen, Dorte Rønnov-Jessen, Jørn Starklint, Mikael Frederiksen, Morten Saabye Steffensen, Ole Weis Bjerrum, Sarah Farmer, Torben Mourits-Andersen, Hans Carl Hasselbalch, Thomas Stauffer Larsen

    1 Citation (Scopus)


    Polycythaemia vera, essential thrombocytosis and primary myelofibrosis are closely related, clonal myeloproliferative neoplasms. Our knowledge of the underlying molecular mechanisms driving these diseases has increased dramatically during the latest ten years. Traditionally, treatment of these malignancies has focused on lowering their inherent thromboembolic risk but with the discovery of the JAK2-V617F mutation and most recently the calreticulin mutations new therapeutic options such as interferon-alpha, JAK2-inhibitors and statins are being contemplated. This article reviews these new treatment options.

    Translated title of the contributionStatus and perspectives on chronic myeloproliferative neoplasm treatment
    Original languageDanish
    JournalUgeskrift for Laeger
    Issue number19
    Publication statusPublished - 4 May 2015


    Dive into the research topics of 'Status and perspectives on chronic myeloproliferative neoplasm treatment'. Together they form a unique fingerprint.

    Cite this